降尿酸药物在冠心病合并高尿酸血症介入术患者中的应用

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the preventive effect of uric acid lowering drugs on coronary artery disease complicated with contrast-induced nephropathy (CIN), and the effect on hypersensitive C reactive protein (hs-CRP) levels.Methods A total of 90 patients who were hospitalized in the Department of Cardiology of the Zengcheng District People′s Hospital of Guangzhou from January 2017 to January 2019 and were diagnosed with coronary heart disease and hyperuricemia were admitted to the hospital for coronary angiography or stent implantation patient.Random number table method was used to divide patients into control group, febuxostat group and benzbromarone group, 30 cases in each group.Patients were treated with secondary prevention of coronary heart disease before angiography or stent implantation.The patients in the febuxostat group was treated with Febuxostat 40 mg/d 24 hours before surgery, and the patients in the benzbromarone group was treated with Benzbromarone 50 mg/d 24 hours before surgery.The patients in the control group did not receive any uric acid lowering drugs.The levels of blood creatinine, blood uric acid, cystatin C (Cys-C), and hs-CRP were compared among the three groups at 48 hours before surgery and 72 hours after surgery,and the incidence of CIN was recorded.Results There were no significant differences in serum creatinine and Cys-C levels among the three groups after 72 hours (P＞0.05).The blood uric acid and hs-CRP of the febuxostat group and benzbromarone group at 72 hours after surgery were lower than those of the control group (P＜0.05).The blood uric acid level in the febuxostat group and the benzbromarone group at 72 hours after surgery was lower than that at 48 hours before surgery, the difference was statistically significant (P＜0.05).The levels of serum creatinine, Cys-C and hs-CRP at 72 hours after surgery in febuxostat group and benzbromarone group were compared with 48 hours before surgery, the differences were not statistically significant (P＞0.05).The incidence of CIN in the febuxostat group was 13.33% (4/30),the incidence of CIN in the benzbromarone group was 13.33% (4/30), and the incidence of CIN in the control group was 16.67% (5/30).There was no significant difference in the incidence of CIN among groups (P＞0.05).Conclusion Starting uric acid lowering therapy 24 hours before surgery cannot reduce the incidence of CIN in patients with coronary heart disease and hyperuricemia, but it can reduce the level of hs-CRP.The effect on long-term renal function after surgery needs further study.

Key words： Coronary heart disease Hyperuricemia Contrast-induced nephropathy Febuxostat Benbromarone

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Qian-e
	CAI Qin-hong
	HUANG Yu-qing
	ZHU Hong-guo

Cite this article:

HUANG Qian-e,CAI Qin-hong,HUANG Yu-qing, et al. Application of uric acid lowering drugs in interventional patients with coronary heart disease and hyperuricemia[J]. 中国当代医药, 2020, 27(23): 50-53.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I23/50

[1]	Abe M，Morimoto T，Nakagawa Y，et al.Impact of transient or persistent contrast-induced nephropathy on long-term mortality after elective percutaneous coronary intervention[J].Am J Cardiol，2017，120（12）：2146-2153.
[2]	Zheng X，Curtis JP，Hu S，et al.Coronary catheterization and percutaneous coronary intervention in China：10-year results from the China PEACE-Retrospective CathPCI study[J].JAMA Intern Med，2016，176（4）：512-521.
[3]	Barbieri L，Verdoia M，Schaffer A，et al.Uric acid levels and the risk of contrast induced nephropathy in patients undergoing coronary angiography or PCI[J].Nutr Metab Cardiovasc Dis，2015，25（2）：181-186.
[4]	Mendi MA，Afsar B，Oksuz F，et al.Uric acid is a useful tool to predict contrast-induced nephropathy[J].Angiology，2017，68（7）：627-632.
[5]	中华医学会内分泌学分会.高尿酸血症和痛风治疗的中国专家共识[J].中华内分泌代谢杂志，2013，29（11）：913-920.
[6]	Park SH，Shin WY，Lee EY，et al.The impact of hyperuricemia on in-hospital mortality and incidence of acute kidney injury in patients undergoing percutaneous coronary intervention[J].Circ J，2011，75（3）：692-697.
[7]	Chonchol M，Shlipak MG，Katz R，et al.Relationship of uric acid with progression of kidney disease[J].Am J Kidney Dis，2007，50（2）：239-247.
[8]	Bo S，Cavallo-Perin P，Gentile L，et al.Hypouricemia and hyperuricemia in type 2 diabetes：two different phenotypes[J].Eur J Clin Invest，2001，31（4）：318-321.
[9]	Khosla UM，Zharikov S，Finch JL，et al.Hyperuricemia induces endothelial dysfunction[J].Kidney Int，2005，67（5）：1739-1742.
[10]	Kang DH，Park SK，Lee IK，et al.Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells[J].J Am Soc Nephrol，2005，16（12）：3553-3562.
[12]	Kang DH，Kim JH，Shin KS，et al.Uric acid induced apoptosis of HUVEC via ROS-dependent path-way，but not of HVSMC[J].J Am Soc Nephrol，2005，16：167A.
[13]	贾万明，牛素贞.血尿酸对冠心病合并糖尿病患者造影剂肾病发生率的影响[J].中国动脉硬化杂志，2018，26（5）：503-506.
[11]	Kanellis J，Watanabe S，Li JH，et al.Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2[J].Hypertension，2003，41（6）：1287-1293.
[14]	Liu Y，Tan N，Chen J，et al.The relationship between hyperuricemia and the risk of contrast-induced acute kidney injury after percutaneous coronary intervention in patients with relatively normal serum creatinine[J].Clinics（Sao Paulo），2013，68（1）：19-25.
[15]	Erol T，Tekin A，Katircibasi MT，et al.Efficacy of allopurinolpretreatmentforpreventionofcontrast-induced nephropathy：a randomized controlled trial[J].Int J Cardiol，2013，167（4）：1396-1399.
[16]	Ghelich Khan Z，Talasaz AH，Pourhosseini H，et al.Potential RoleofAllopurinolinPreventingContrast-InducedNephropathy in Patients Undergoing Percutaneous Coronary Intervention: A Randomized Placebo-Controlled Trial[J].Clin Drug Investig，2017，37（9）：853-860.